The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD‐1/L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study
Xiaobing Li, De Wu, Yi Peng, Jing Tang, Yuebing Wu · 2024
Read The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD‐1/L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study by Xiaobing Li, De Wu, Yi Peng, Jing Tang, Yuebing Wu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11632393.txt.
Description
Xiaobing Li and four co-authors review a three-drug mix for a hard-to-treat lung cancer group, in this 2024 paper. The patients had small cell lung cancer that had spread widely, including to the brain. Their outlook is poor and good options are few. The mix joins a chemo drug, a blood-vessel blocker, and immune therapy drugs.
The team looked back at 55 patients who got the mix. About 36 percent saw their tumors shrink, and the middle survival time was ten months, with five months before the disease grew again. A standard outlook score helped predict who did best. Side effects were common but mostly mild, and the authors link the mix's power to reduced immune suppression. They call for larger, forward-looking studies to test the approach.
Catalog record
| CREATOR | Xiaobing Li, De Wu, Yi Peng, Jing Tang, Yuebing Wu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |